Global Naloxone Market Insights, Forecast to 2025

2 Global Naloxone Quarterly Market Size Analysis

• 2.1 Naloxone Business Impact Assessment - COVID-19
  • 2.1.1 Global Naloxone Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
  • 2.1.2 Global Naloxone Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Naloxone Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 Global Naloxone Quarterly Market Size by Manufacturers, 2019 VS 2020
• 3.2 Global Naloxone Factory Price by Manufacturers
• 3.3 Location of Key Manufacturers Naloxone Manufacturing Factories and Area Served
• 3.4 Date of Key Manufacturers Enter into Naloxone Market
• 3.5 Key Manufacturers Naloxone Product Offered
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Naloxone Segments, By Type

• 4.1 Introduction
  • 1.4.1 Spray forms
  • 1.4.2 Injectable forms
• 4.2 By Type, Global Naloxone Market Size, 2019-2021
  • 4.2.1 By Type, Global Naloxone Market Size by Type, 2020-2021
  • 4.2.2 By Type, Global Naloxone Price, 2020-2021

5 Impact of Covid-19 on Naloxone Segments, By Application

• 5.1 Overview
  • 5.5.1 Opioid overdose
  • 5.5.2 Preventing opioid abuse
• 5.2 By Application, Global Naloxone Market Size, 2019-2021
  • 5.2.1 By Application, Global Naloxone Market Size by Application, 2019-2021
  • 5.2.2 By Application, Global Naloxone Price, 2020-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 ADAPT Pharma
  • 7.1.1 ADAPT Pharma Business Overview
  • 7.1.2 ADAPT Pharma Naloxone Quarterly Production and Revenue, 2020
  • 7.1.3 ADAPT Pharma Naloxone Product Introduction
  • 7.1.4 ADAPT Pharma Response to COVID-19 and Related Developments
• 7.2 Amphastar Pharmaceuticals
  • 7.2.1 Amphastar Pharmaceuticals Business Overview
  • 7.2.2 Amphastar Pharmaceuticals Naloxone Quarterly Production and Revenue, 2020
  • 7.2.3 Amphastar Pharmaceuticals Naloxone Product Introduction
  • 7.2.4 Amphastar Pharmaceuticals Response to COVID-19 and Related Developments
• 7.3 Pfizer
  • 7.3.1 Pfizer Business Overview
  • 7.3.2 Pfizer Naloxone Quarterly Production and Revenue, 2020
  • 7.3.3 Pfizer Naloxone Product Introduction
  • 7.3.4 Pfizer Response to COVID-19 and Related Developments
• 7.4 kaleo
  • 7.4.1 kaleo Business Overview
  • 7.4.2 kaleo Naloxone Quarterly Production and Revenue, 2020
  • 7.4.3 kaleo Naloxone Product Introduction
  • 7.4.4 kaleo Response to COVID-19 and Related Developments
• 7.5 Sandoz
  • 7.5.1 Sandoz Business Overview
  • 7.5.2 Sandoz Naloxone Quarterly Production and Revenue, 2020
  • 7.5.3 Sandoz Naloxone Product Introduction
  • 7.5.4 Sandoz Response to COVID-19 and Related Developments
• 7.6 Amneal Pharmaceuticals
  • 7.6.1 Amneal Pharmaceuticals Business Overview
  • 7.6.2 Amneal Pharmaceuticals Naloxone Quarterly Production and Revenue, 2020
  • 7.6.3 Amneal Pharmaceuticals Naloxone Product Introduction
  • 7.6.4 Amneal Pharmaceuticals Response to COVID-19 and Related Developments
• 7.7 West Ward Pharmaceuticals
  • 7.7.1 West Ward Pharmaceuticals Business Overview
  • 7.7.2 West Ward Pharmaceuticals Naloxone Quarterly Production and Revenue, 2020
  • 7.7.3 West Ward Pharmaceuticals Naloxone Product Introduction
  • 7.7.4 West Ward Pharmaceuticals Response to COVID-19 and Related Developments
• 7.8 Mylan
  • 7.8.1 Mylan Business Overview
  • 7.8.2 Mylan Naloxone Quarterly Production and Revenue, 2020
  • 7.8.3 Mylan Naloxone Product Introduction
  • 7.8.4 Mylan Response to COVID-19 and Related Developments

8 Supply Chain and Sales Channels Analysis

• 8.1 Naloxone Supply Chain Analysis
  • 8.1.1 Naloxone Supply Chain Analysis
  • 8.1.2 Covid-19 Impact on Naloxone Supply Chain
• 8.2 Distribution Channels Analysis
  • 8.2.1 Naloxone Distribution Channels
  • 8.2.2 Covid-19 Impact on Naloxone Distribution Channels
  • 8.2.3 Naloxone Distributors
• 8.3 Naloxone Customers

9 Key Findings

10 Appendix

• 10.1 About Us